Can BioNTech Thrive Beyond the Pandemic Vaccine Boom?
BioNTech transitions from COVID-19 vaccine success to a focus on mRNA cancer therapies. 2024 earnings per share dropped to €1.08, exceeding market forecasts; revenue also surpassed expectations despite a decline.…